
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Document Content</title>
    <style>
        body { font-family: Arial, sans-serif; line-height: 1.6; max-width: 900px; margin: auto; padding: 20px; }
        table { border-collapse: collapse; width: 100%; margin-top: 20px; margin-bottom: 20px; }
        th, td { border: 1px solid #cccccc; text-align: left; padding: 8px; font-size: 12px; }
        tr:nth-child(even) { background-color: #f9f9f9; }
        th { background-color: #3366CC; color: white; font-weight: bold; }
        h2 { color: #4F81BD; border-bottom: 2px solid #4F81BD; padding-bottom: 5px;}
        p { margin-block-start: 0.5em; margin-block-end: 0.5em; }
    </style>
</head>
<body>
    <p style="font-size: small; color: grey;"><i>Document</i></p>
<p style="font-size: small; color: grey;"><i>Page 48 of 123</i></p>
<p style="font-size: small; color: grey;"><i>AKORN_10k_048.pdf</i></p>
<p>AKORN, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands)</p>

<table>
	<tr>
		<th rowspan="2"></th>
		<th colspan="3">Year ended December 31,</th>
	</tr>
	<tr>
		<th>2017</th>
		<th>2016</th>
		<th>2015</th>
	</tr>
	<tr>
		<td>OPERATING ACTIVITIES:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Consolidated net (loss) income</td>
		<td>$ (24,550)</td>
		<td>$ 184,243</td>
		<td>$ 150,798</td>
	</tr>
	<tr>
		<td>Adjustments to reconcile consolidated net (loss) income to net cash provided by operating activities:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Depreciation and amortization</td>
		<td>85,173</td>
		<td>87,963</td>
		<td>86,924</td>
	</tr>
	<tr>
		<td>Impairment of intangible assets</td>
		<td>128,127</td>
		<td>44,369</td>
		<td>33,003</td>
	</tr>
	<tr>
		<td>Amortization of deferred financing fees</td>
		<td>5,216</td>
		<td>10,760</td>
		<td>4,350</td>
	</tr>
	<tr>
		<td>Amortization of favorable contracts</td>
		<td>—
</td>
		<td>—</td>
		<td>71</td>
	</tr>
	<tr>
		<td>Amortization of inventory step-up</td>
		<td>—
</td>
		<td>—
</td>
		<td>4,681</td>
	</tr>
	<tr>
		<td>Non-cash stock compensation expense</td>
		<td>21,018</td>
		<td>15,412</td>
		<td>12,997</td>
	</tr>
	<tr>
		<td>Non-cash interest expense</td>
		<td>—</td>
		<td>777</td>
		<td>2,778</td>
	</tr>
	<tr>
		<td>Non-cash gain on bargain purchase</td>
		<td>—
</td>
		<td>—</td>
		<td>(849)</td>
	</tr>
	<tr>
		<td>Income from available-for-sale securities</td>
		<td>(3,032)</td>
		<td>—
</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Deferred income taxes, net</td>
		<td>(115,249)</td>
		<td>(32,934)</td>
		<td>(46,130)</td>
	</tr>
	<tr>
		<td>Excess tax benefit from stock compensation</td>
		<td>—</td>
		<td>—</td>
		<td>(47,997)</td>
	</tr>
	<tr>
		<td>Loss on extinguishment of debt</td>
		<td>—
</td>
		<td>—
</td>
		<td>1,243</td>
	</tr>
	<tr>
		<td>Gain on sale of available-for-sale security</td>
		<td>199</td>
		<td>45</td>
		<td>237</td>
	</tr>
	<tr>
		<td>Other</td>
		<td>(307)</td>
		<td>(4,888)</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Changes in operating assets and liabilities:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Trade accounts receivable, net</td>
		<td>141,979</td>
		<td>(132,617)</td>
		<td>40,287</td>
	</tr>
	<tr>
		<td>Inventories, net</td>
		<td>(8,367)</td>
		<td>10,208</td>
		<td>(50,729)</td>
	</tr>
	<tr>
		<td>Prepaid expenses and other current assets</td>
		<td>(14,120)</td>
		<td>(6,494)</td>
		<td>17,574</td>
	</tr>
	<tr>
		<td>Trade accounts payable</td>
		<td>(9,223)</td>
		<td>6,139</td>
		<td>(4,819)</td>
	</tr>
	<tr>
		<td>Accrued expenses and other liabilities</td>
		<td>42,400</td>
		<td>(15,224)</td>
		<td>93,229</td>
	</tr>
	<tr>
		<td>NET CASH PROVIDED BY OPERATING ACTIVITIES</td>
		<td>249,264</td>
		<td>167,759</td>
		<td>297,648</td>
	</tr>
	<tr>
		<td>INVESTING ACTIVITIES:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Payments for acquisitions and equity investments, net of cash acquired</td>
		<td>—</td>
		<td>—
</td>
		<td>(24,408)</td>
	</tr>
	<tr>
		<td>Proceeds from disposal of assets</td>
		<td>4,815</td>
		<td>5,966</td>
		<td>2,459</td>
	</tr>
	<tr>
		<td>Payments for other intangible assets</td>
		<td>(200)</td>
		<td>(3,950)</td>
		<td>(3,835)</td>
	</tr>
	<tr>
		<td>Purchases of property, plant and equipment</td>
		<td>(95,170)</td>
		<td>(74,938)</td>
		<td>(27,934)</td>
	</tr>
	<tr>
		<td>NET CASH USED IN INVESTING ACTIVITIES</td>
		<td>(90,555)</td>
		<td>(72,922)</td>
		<td>(53,718)</td>
	</tr>
	<tr>
		<td>FINANCING ACTIVITIES:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Proceeds under stock option and stock purchase plans</td>
		<td>7,594</td>
		<td>9,795</td>
		<td>11,916</td>
	</tr>
	<tr>
		<td>Payments of contingent acquisition liabilities</td>
		<td>—
</td>
		<td>—</td>
		<td>(8,991)</td>
	</tr>
	<tr>
		<td>Debt financing costs</td>
		<td>—

</td>
		<td>(5,128)</td>
		<td>(8,564)</td>
	</tr>
	<tr>
		<td>Excess tax benefits from stock compensation</td>
		<td>—</td>
		<td>—</td>
		<td>47,997</td>
	</tr>
	<tr>
		<td>Common stock repurchases</td>
		<td>—
</td>
		<td>(45,000)</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Debt repayment</td>
		<td>—
</td>
		<td>(200,000)</td>
		<td>(10,450)</td>
	</tr>
	<tr>
		<td>NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES</td>
		<td>7,594</td>
		<td>(240,333)</td>
		<td>31,908</td>
	</tr>
	<tr>
		<td>Effect of changes in exchange rates on cash and cash equivalents</td>
		<td>1,044</td>
		<td>2</td>
		<td>(251)</td>
	</tr>
	<tr>
		<td>INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</td>
		<td>167,347</td>
		<td>(145,494)</td>
		<td>275,587</td>
	</tr>
	<tr>
		<td>CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</td>
		<td>200,772</td>
		<td>346,266</td>
		<td>70,679</td>
	</tr>
	<tr>
		<td>CASH AND CASH EQUIVALENTS AT END OF YEAR</td>
		<td>$ 368,119</td>
		<td>$ 200,772</td>
		<td>$ 346,266</td>
	</tr>
</table>
<p>—</p>
<p>71</p>
<p>Amortization of inventory step-up</p>
<p>—
</p>
<p>—
</p>
<p>4,681</p>
<p>Non-cash stock compensation expense</p>
<p>21,018</p>
<p>15,412</p>
<p>12,997</p>
<p>Non-cash interest expense</p>
<p>—</p>
<p>777</p>
<p>2,778</p>
<p>Non-cash gain on bargain purchase</p>
<p>—
</p>
<p>—</p>
<p>(849)</p>
<p>Income from available-for-sale securities</p>
<p>(3,032)</p>
<p>—
</p>
<p>—</p>
<p>Deferred income taxes, net</p>
<p>(115,249)</p>
<p>(32,934)</p>
<p>(46,130)</p>
<p>Excess tax benefit from stock compensation</p>
<p>—</p>
<p>—</p>
<p>(47,997)</p>
<p>Loss on extinguishment of debt</p>
<p>—
</p>
<p>—
</p>
<p>1,243</p>
<p>Gain on sale of available-for-sale security</p>
<p>199</p>
<p>45</p>
<p>237</p>
<p>Other</p>
<p>(307)</p>
<p>(4,888)</p>
<p>—</p>
<p>Changes in operating assets and liabilities:</p>
<p>Trade accounts receivable, net</p>
<p>141,979</p>
<p>(132,617)</p>
<p>40,287</p>
<p>Inventories, net</p>
<p>(8,367)</p>
<p>10,208</p>
<p>(50,729)</p>
<p>Prepaid expenses and other current assets</p>
<p>(14,120)</p>
<p>(6,494)</p>
<p>17,574</p>
<p>Trade accounts payable</p>
<p>(9,223)</p>
<p>6,139</p>
<p>(4,819)</p>
<p>Accrued expenses and other liabilities</p>
<p>42,400</p>
<p>(15,224)</p>
<p>93,229</p>
<p>NET CASH PROVIDED BY OPERATING ACTIVITIES</p>
<p>249,264</p>
<p>167,759</p>
<p>297,648</p>
<p>INVESTING ACTIVITIES:</p>
<p>Payments for acquisitions and equity investments, net of cash acquired</p>
<p>—</p>
<p>—
</p>
<p>(24,408)</p>
<p>Proceeds from disposal of assets</p>
<p>4,815</p>
<p>5,966</p>
<p>2,459</p>
<p>Payments for other intangible assets</p>
<p>(200)</p>
<p>(3,950)</p>
<p>(3,835)</p>
<p>Purchases of property, plant and equipment</p>
<p>(95,170)</p>
<p>(74,938)</p>
<p>(27,934)</p>
<p>NET CASH USED IN INVESTING ACTIVITIES</p>
<p>(90,555)</p>
<p>(72,922)</p>
<p>(53,718)</p>
<p>FINANCING ACTIVITIES:</p>
<p>Proceeds under stock option and stock purchase plans</p>
<p>7,594</p>
<p>9,795</p>
<p>11,916</p>
<p>Payments of contingent acquisition liabilities</p>
<p>—
</p>
<p>—</p>
<p>(8,991)</p>
<p>Debt financing costs</p>
<p>—

</p>
<p>(5,128)</p>
<p>(8,564)</p>
<p>Excess tax benefits from stock compensation</p>
<p>—</p>
<p>—</p>
<p>47,997</p>
<p>Common stock repurchases</p>
<p>—
</p>
<p>(45,000)</p>
<p>—</p>
<p>Debt repayment</p>
<p>—
</p>
<p>(200,000)</p>
<p>(10,450)</p>
<p>NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES</p>
<p>7,594</p>
<p>(240,333)</p>
<p>31,908</p>
<p>Effect of changes in exchange rates on cash and cash equivalents</p>
<p>1,044</p>
<p>2</p>
<p>(251)</p>
<p>INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</p>
<p>167,347</p>
<p>(145,494)</p>
<p>275,587</p>
<p>CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</p>
<p>200,772</p>
<p>346,266</p>
<p>70,679</p>
<p>CASH AND CASH EQUIVALENTS AT END OF YEAR</p>
<p>$ 368,119</p>
<p>$ 200,772</p>
<p>$ 346,266</p>
<p>See notes to the consolidated financial statements.</p>
<p style="font-size: small; color: grey;"><i>file://usmdcvdi003.us.kworld.kpmg.com/GDC_Ops/Operations/Gayathri%20Krishnan/RPA%20Phase%20II/Kiran/HealthCare/ ... 7/23/2018</i></p>
<p style="font-size: small; color: grey;"><i>48</i></p>

</body>
</html>
